The Future of Eliquis





Who the hell do you work for? Every target I call on is a cardiologist

Oh, you must be one of those very special cardiology "specialty" reps who never answers our phone calls. Hello, clueless! We are the rest of your entire district full of primary care reps and also Pfizer counterparts who are part of your "team" supporting Eliquis! I know you have been extremely busy giving hospital "in-services", (wink, smile), so you have no time for the rest of us lowly primary care minions on the team.
 




































I don't understand this statement. While Eliquis start up was much slower than expected it is growing in share every week. Pradaxa and Xarelto are tough competitors and good drugs. I currently have a 35% share of new RXs. While I'm above average it is clear that Eliquis is getting a lot of business and it is with those prescribers who are reading and interpreting the data. Eliquis's data has stood the test of intense scrutiny and after just a year and a half is getting close to taking a third of the market.

If anyone is interested at all in the timeline of when Eliquis trajectory started improving it was around Oct. 2013 and has been on a steady incline since. Who was brought into the team around that time period. You folks should probably give them a little thanks.